Having inhouse manufacturing capabilities gives cell and gene therapy developers a competitive advantage

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
As cell and gene therapies progress through the clinic, developers are looking to secure manufacturing capabilities. Within the CDMO space, unprecedented demand for services is driving facility expansions and a whole new M&A focus. But a growing number of end-users are opting to move away from outsourcing partners and invest in their own cell and gene networks. Pfizer is building a $500 million NC plant, Novartis bought its CAR-T CDMO CellForCure, and Astellas acquired Audentes for $3 billion, citing the addition of an AAV facility as motivation. So will having inhouse capabilities provide an advantage as the sector matures? This panel hopes to find out…

Chair: Dan Stanton, BioProcess Insider
Panelist: Joe Rininger, Latham Biopharm Group
Panelist: Felix Hsu, SVP and Global Head, WuXi Advanced Therapies
Panelist: TBA, Miltenyi Biotech
Sponsored By